(MedPage Today) — SAN DIEGO — Patients with operable non-small cell lung cancer (NSCLC) had significantly longer event-free survival (EFS) with perioperative chemoimmunotherapy, a large randomized trial from China showed.
After a median follow…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






